A new study just published in the Journal of Medical Economics titled “Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections” found that the FebriDx® test could save the United Kingdom’s healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.
- Click here to access the study.
- Click here to read a press release about the study.
The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on FebriDx, visit febridx.com.
Media contact: Saranova, LLC • [email protected] • +1.941.928.9025
New Study Suggests FebriDx® as a ‘Front Door Triage Tool’ in the Fight Against COVID-19
A new study in the Journal of Infection by Dr. Tristan Clark, et al. titled “Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19” identifies the FebriDx® test as a rapid, highly accurate, and affordable ‘front door triage tool’ to help healthcare providers differentiate viral from bacterial infection in patients with suspected COVID-19.